Use of Valganciclovir/Ganciclovir [(v)GCV] for Treatment of Congenital Cytomegalovirus (cCMV) Infection in the United States: Evidence from the Sentinel Distributed Database, 2008-2020

Ashish Rai[1], Emmanuel Ojo[1], Takashi E. Komatsu[2], Mayura Shinde[1], Danijela Stojanovic[2], Adebola Ajao[2], Hengrui Sun[2], Amy Bishara[2], Joy Kolonoski[1], Ann McMahon[2], Prabha Viswanathan[2]

[1] Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA ;
[2] U.S. Food and Drug Administration, United States

ABSTRACT

This is a descriptive analysis to determine the patterns of cCMV diagnosis, trends in prescribing (v)GCV for treatment of cCMV, and associated clinical characteristics for infants with cCMV in the United States

BACKGROUND

- Congenital cytomegalovirus infection (cCMV) is associated with serious audiologic and neurodevelopmental impairment.
- There are no FDA-approved agents to prevent or treat cCMV infection.
- Six months of valganciclovir (which could include IV ganciclovir) [(v)GCV] initiated within the 1st month of life is recommended for newborns with moderate to severe disease [1,2,3].
- The full extent of uptake of these recommendations is unknown. It is also unknown whether patients with less severe disease are being treated with (v)GCV.
- The safety profile of (v)GCV has been well-established in other populations, but data from congenitally infected infants remain more limited [4].

OBJECTIVES

The goal of this work is to address knowledge gaps that impact the development of antivirals to treat cCMV. The specific aims of this study include:

- To assess features of (v)GCV treatment for infants with cCMV in the United States, with a focus on the following:
  - Changes in (v)GCV prescribing over time
  - Correlation of (v)GCV treatment and baseline disease severity
- To characterize the frequency and severity of hematologic toxicity associated with (v)GCV exposure.
- To assess audiological outcomes among children with cCMV, and to consider the impact of (v)GCV treatment on those outcomes.

METHODS

Main Analysis

- The FDA Sentinel System's Distributed Database [5] was used to identify three cohorts of infants with diagnosis codes reflecting cCMV infection from 2008-2021, as shown in Figures 1 and 2:
  - Group 1: all infants with cCMV diagnosed in the 1st45 days of life
  - Group 2: Group 1 infants who were treated with (v)GCV within 45 days of cCMV diagnosis
  - Group 3: Group 1 infants who were treated with (v)GCV within 180 days of cCMV diagnosis
- The study included infants diagnosed up to 45 days of life to allow sufficient time for cCMV-related codes to be identifiable in the infant's record.
- Characteristics assessed at baseline include demographic information and cCMV-associated clinical features documented within 15 days of cCMV diagnosis (note, 30 days was permitted for CNS radiology studies).
- Group 1 infants were categorized into one of four categories based on the presence/absence of baseline clinical features: asymptomatic; isolated hearing loss; clinical symptoms, no hearing loss; and clinical symptoms with hearing loss
- Hearing loss was reassessed at 60, 180, and 365 days; hematologic safety outcomes were assessed at 60 and 180 days.

Secondary Analysis

- Duration of treatment was also assessed among all patients up to 5 years of age who received (v)GCV AND had a congenital CMV diagnosis code at any time code prior to, and through 45 days after, the first (v)GCV exposure.

RESULTS

Main Analysis

- A total of 1,500 infants with cCMV infection were identified (Group 1). At baseline, 405 (27%) were asymptomatic, 38 (3%) had isolated hearing loss, 963 (64%) had clinical symptoms without hearing loss, and 94 (6%) had clinical symptoms and hearing loss.
- Treatment with (v)GCV was initiated within 45 days of diagnosis for 221 (15%) infants (Group 2) and within 180 days for 301 (20%) infants (Group 3).

Figure 2: Group 2/3 Design Diagram



nds in diagnosis of
IV and treatment
n (v)GCV over time
shown by Group in
ure 3.

e: data from 2020
2021 are incomplete
the trend should be
rpreted accordingly.

The primary results of the study are summarized in Table 1.

- Jaundice, thrombocytopenia, and brain abnormalities were the most common clinical manifestations at the time of diagnosis.
- Neutropenia occurred more frequently among children treated with (v)GCV but few needed treatment with G-CSF.
- (v)GCV did not appear to increase the risk of severe anemia or thrombocytopenia requiring transfusions.
- The proportion of patients with hearing loss increased over time in all groups, irrespective of (v)GCV exposure.

Table 1: Main Analysis Results, 2008-2021

	Group 1: All infants N = 1,500	Group 2: (v)GCV within 45 days N=221	Group 3: (v)GCV within 180 days N=301
Demographic Characteristics			
Mean Age in days (Standard Deviation)	7.6 (11.5)	9.0 (12.3)	8.0 (11.8)
Sex			
Male	809 (53.9)	116 (52.5)	159 (52.8)
Female	691 (46.1)	105 (47.5)	142 (47.2)
Clinical Symptoms at Baseline			
Jaundice	731 (48.7)	105 (47.5)	144 (47.8)
Petechiae	84 (5.6)	33 (14.9)	37 (12.3)
Hepatomegaly	73 (4.9)	18 (18.1)	24 (8.0)
Splenomegaly	53 (3.5)	18 (18.1)	25 (8.3)
Microcephaly	123 (8.2)	36 (16.3)	50 (16.6)
Thrombocytopenia	542 (36.1)	97 (43.9)	141 (46.8)
Chorioretinitis	44 (2.9)	13 (5.9)	16 (5.3)
Brain abnormality	279 (18.6)	75 (34.0)	96 (31.9)

	Group 1: All infants N = 1,500	Group 2: (v)GCV within 45 days N=221	Group 3: (v)GCV within 180 days N=301
Hematological Safety Outcomes (60 days)			
Neutropenia	210 (14.0)	41 (18.6)	64 (21.3)
G-CSF†	6 (0.4)	3 (1.4)	4 (1.3)
pRBC transfusion‡	118 (7.9)	7 (3.2)	17 (5.6)
Platelet transfusion	85 (5.7)	14 (6.3)	23 (7.6)
Hematological Safety Outcomes (180 days)			
Neutropenia	244 (16.3)	57 (25.8)	85 (28.2)
G-CSF†	12 (0.8)	7 (3.2)	8 (2.7)
pRBC transfusion‡	122 (8.1)	7 (3.2)	19 (6.3)
Platelet transfusion	90 (6.0)	14 (6.3)	24 (8.0)
Hearing Loss			
Baseline	132 (8.8)	49 (22.2)	58 (19.3)
60 Days	204 (13.6)	87 (39.4)	103 (34.2)
180 Days	318 (21.2)	124 (56.1)	155 (51.5)
365 Days	387 (25.8)	138 (62.4)	175 (58.1)

† G-CSF: granulocyte colony stimulating factor
‡ pRBC: Packed red blood cells

Secondary Analysis

- A total of 302 patients with a diagnosis of cCMV started (v)GCV before 5 years of age, as summarized in Table 2.
- The overall duration of treatment was variable and there was no clear association between baseline disease severity and length of treatment.

Table 2: Secondary Analysis Results, 2008-2021

	Duration of Treatment					
Baseline Disease Severity N (%)	≤30 days N=0 n (%)	31-90 days N=104 n (%)	91-180 days N=84 n (%)	181-365 days N=107 n (%)	>365 days N=7 n (%)	Total N=302 n (%)
Asymptomatic	0 (0%)	22 (21%)	15 (18%)	14 (13%)	0 (0%)	51 (17%)
Isolated hearing loss	0 (0%)	10 (10%)	7 (8%)	8 (7%)	2 (29%)	27 (9%)
Clinical symptoms, no hearing Loss	0 (0%)	56 (54%)	49 (58%)	60 (56%)	5 (71%)	170 (56%)
Clinical symptoms + hearing loss	0 (0%)	16 (15%)	13 (15%)	25 (23%)	0 (0%)	54 (18%)

CONCLUSIONS

- In a large cohort of infants with cCMV, 20% were treated with (v)GCV.
- Although clinical severity cannot be determined from claims data, the results suggest that (v)GCV treatment in the US may extend beyond the current recommendations.
  - 17% of the treated population were asymptomatic around the cCMV diagnosis.
  - 80 patients (27%) began (v)GCV treatment outside of the neonatal period.
  - 114 patients (38%) received (v)GCV for longer than 6 months.
- Severe hematological events occurred infrequently.
- The proportion of patients with hearing loss increased over time, regardless of treatment.
- Additional work assessing patient-level data are needed to further our understanding of the current treatment landscape for cCMV. This work is ongoing by this study team.

LIMITATIONS

- The positive predictive value of the cCMV billing codes are unknown as the codes were not validated. This likely overestimates the number of cCMV cases captured in our study.
  - The cohort may include children with suspected but unconfirmed cCMV.
  - Children with postnatally acquired CMV could potentially be misclassified as cCMV cases.
- Health insurance claims data are subject to inherent limitations such as differences in coding practices.
- Since these data come primarily from commercially insured children, the findings may not be generalizable to the US population at large.

REFERENCES

1. Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, editors. Red Book: 2021-2024 Report of the Committee on Infectious Diseases (32nd Edition). Elk Grove Village, IL: American Academy of Pediatrics, 2021. Cytomegalovirus Infection; p. 294-300.
2. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017;17: e177-88.
3. Kimberlin DW, Jester PM, Sanchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372:933-943
4. VALCYTE prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021304.s17_22257s12lbl.pdf. Accessed March 3, 2022.
5. FDA's Sentinel System (https://www.sentinelinitiative.org/).

ACKNOWLEDGEMENTS/DISCLOSURES

- This project was supported by Task Order 75F40119F19001 under Master Agreement 75F40119D10037 from the US Food and Drug Administration (FDA).
- Many thanks are due to the Sentinel Data Partners who provided data used in the analysis.
- The authors have no conflicts of interest to disclose.
- The views expressed in this presentation represent those of the presenters and do not necessarily represent the official views of the U.S. FDA.